Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03891329
Other study ID # TA115
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 30, 2019
Est. completion date September 24, 2021

Study information

Verified date January 2022
Source Biotronik SE & Co. KG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Post-Market Clinical Follow-up of the new Cor Family ICDs/CRT-Ds (Acticor, Rivacor) and the new Plexa ProMRI S DX right ventricular lead to provide post-market data and supporting evidence for the clinical safety and performance of the devices.


Recruitment information / eligibility

Status Completed
Enrollment 130
Est. completion date September 24, 2021
Est. primary completion date December 21, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Standard indication for ICD or CRT-D therapy according to clinical guidelines - Planned for de novo implantation of an ICD/CRT-D, or upgrade/exchange from existing ICD/CRT-D or pacemaker implant - Able to understand the nature of study and to provide written informed consent - Willing and able to perform all follow-up visits at the study site - Willing and able to use the CardioMessenger and accepts the BIOTRONIK Home Monitoring concept Exclusion Criteria: - Contraindication to ICD and CRT-D therapy - Planned for implantation of a CRT-DX system - For VR-T DX devices: permanent atrial tachyarrhythmia - For VR-T DX devices: patients requiring atrial pacing - Less than 18 years old - Pregnant or breast feeding - Participating in another interventional clinical investigation - Life-expectancy is less than 12 months - Cardiac surgical procedure planned within 12 months after implantation (including interventional procedures like ablation, valve replacement, heart transplant etc.). Procedures to occur during or prior to implantation are not exclusionary

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Acticor/Rivacor ICDs/CRT-Ds
pre-defined device programming, measurements and follow-up schedule
Plexa S DX
Implantation, measurements and follow-up schedule

Locations

Country Name City State
Austria Kepler Universitätsklinikum Linz
Germany Herz- und Diabeteszentrum NRW Bad Oeynhausen
Germany Charité Universitätsmedizin Berlin Berlin
Germany SRH Wald-Klinikum Gera GmbH Gera
Germany SRH Zentralklinikum Suhl Suhl
Hungary National Hospital of Cardiology Balatonfüred
Hungary Semmelweis Medical University Budapest
Latvia Pauls Stradins Clinical University Hospital Riga
Netherlands Hospital Medisch Spectrum Twente Enschede
Netherlands Erasmus Medical Center Rotterdam
Slovakia East-Slovak Cardiology Institute (VUSCH) Košice
Switzerland Inselspital - Universitätsspital Bern Bern
Switzerland Universitätsspital Zürich Zürich

Sponsors (1)

Lead Sponsor Collaborator
Biotronik SE & Co. KG

Countries where clinical trial is conducted

Austria,  Germany,  Hungary,  Latvia,  Netherlands,  Slovakia,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cor Family-related SADE-free rate until 3-month follow-up SADE-free rate related to the Cor Family ICDs/CRT-Ds 3 months
Secondary Kaplan-Meier estimate for the Cor Family related SADE-free rate Application of the Kaplan-Meier method to estimate the 3-month SADE-free rate and the 12-month SADE-free rate 3 months, 12 months
Secondary Assessment of the Automatic LV VectorOpt test (CRT-devices only) by the investigator Investigator appraisal of the Overall handling of the Feature (score: Very good/good/ adequate/poor/very poor) 3 months
Secondary 4. Assessment of the CRT AutoAdapt feature (CRT-devices only) by the investigator Investigator appraisal of the overall handling of the Feature (score: Very good/good/ adequate/poor/very poor) 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy